ClinicalTrials.gg
RecruitingNCT03940911FamuspaUpdated Mar 12, 2026

Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis

An interventional study of Measurement of aerobic exercise on cycloergometer in Spondyloarthritis, Axial, Fatigue and Exercise Capacity, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies in Axial Spondyloarthritis with a site in France — 9 open to participants now, 11 under way, 3 of them phase 3. Axial Spondyloarthritis · France.

Planned enrollment
19th of 30
122 · median 188
Started
2025
with 2 others
No phase
13 of 40
6 open now
Primary completion
2029-12
later than 8 of 10 live
Registered
19th of 40
by date

Among the 40 studies in Axial Spondyloarthritis with a site in France, this one is the 19th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 19th registered.

Axial Spondyloarthritis

187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

9 of the 40 studies in Axial Spondyloarthritis with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Axial Spondyloarthritis studies recruiting now, 20 (51%) set no upper age limit and 13 (33%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Axial Spondyloarthritis with a site in France, or all of them as a file.
02

Study summary

Axial spondyloarthropathy (SpA) is the most common inflammatory rheumatism (1% of the general population) with important medico-economic consequences.

Fatigue is a major feature of SA. It can be defined as a feeling of reduced muscle capacity, lack of energy and exhaustion. The fatigue reaches an abnormally high level (fatigue severity score (FSS) ≥4, called severe fatigue in this protocol) in more than two thirds of patients with SA.

Skeletal muscle repercussions are present during SA. It is characterized by a decrease in exercise capacity independently of pain and ankylosis but is associated with a decrease in strength and muscle mass, the importance of which varies from one study to another.

The link between fatigue (subjective sensation) and the skeletal muscular impact (objective) of SA has never been studied.

Read the detailed description

This work will:

  1. Study for the first time the implication of the objective skeletal muscular impact in fatigue during SA.
  2. Better characterize the skeletal muscle impact of SA;
  3. Characterize the evolution of the fatigue and the muscular impact under targeted therapy
03

Conditions studied

  • Spondyloarthritis, Axial
  • Fatigue
  • Exercise Capacity

Keywords

  • Axial spondylarthritis
  • Fatigue
  • Targeted therapy
  • Exercise capacity
  • Sarcopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Axial SA according to the ASAS criteria;
  • Targeted therapy naïve patients
  • Indication to start a targeted therapy;
  • Initiation of targeted therapy ≤ 15 days before inclusion
  • ≥ 18 years old, no upper age limit;
  • Subject affiliated to a social health insurance reimbursement;
  • Subject able to understand the aims and risks of the research and having signed a dated and
  • Subject informed of the results of the preliminary medical examination
  • Woman in childbearing age: negative beta-HCG test and effective ;
  • Sufficient understanding of French to follow the protocol.

Exclusion criteria

Exclusion criteria:

  • Targeted therapy in progress for > 15 days prior to inclusion
  • to the use of targeted therapy
  • Systemic in the 15 days preceding the V0 visit
  • Associated extramuscular inflammatory disease (s) (excluding ocular and cutaneous involvement) eg chronic inflammatory bowel disease
  • Associated fibromyalgia (Questionnaire score FiRST ≥5) achieved during the V0 visit
  • History of coronary artery disease: exercise angina, acute coronary syndrome and / or coronary angioplasty,
  • History of lower extremity arterial disease: vascular claudication and / or lower extremity angioplasty
  • Neuromuscular pathology
  • Insufficiency of organ (renal, hepatic pulmonary heart)
  • Sleep apnea
  • Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject, etc.)
  • Subject under the protection of justice
  • Subject under guardianship or curatorship
  • Breastfeeding
  • Pregnancy
  • Subject in exclusion period defined by another clinical study or participating in a study likely to impact the results of the research
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (estimated)

Study arms

  • Other
    Targeted therapy and severe fatigue (FSS)

    See bellow (section "Interventions") the full description for * Measurement of aerobic exercise on cycloergometer * Measurement of muscle mass by two-photon absorptiometry: specific study * Measurement of Isometric Muscle Strength * Blood sampling for measurement of cytokine levels in the blood * Measurement of sedentarity * Psychological impact * Fatigue measurement

    Other: Measurement of aerobic exercise on cycloergometer

  • Other
    Targeted therapy and mild fatigue (FSS <4)

    See bellow (section "Interventions") the full description for * Measurement of aerobic exercise on cycloergometer * Measurement of muscle mass by two-photon absorptiometry: specific study * Measurement of Isometric Muscle Strength * Blood sampling for measurement of cytokine levels in the blood * Measurement of sedentarity * Psychological impact * Fatigue measurement

    Other: Measurement of aerobic exercise on cycloergometer

Interventions

  • OtherMeasurement of aerobic exercise on cycloergometer

    The incremental effects tests will be performed in a service specialized in the exploration of the exercise (physiology or cardiology according to the centers) in a spacious and air-conditioned room, in the presence of a medical specialist. exercise and close to the resuscitation equipment. Before the test, weight and height will be collected. Information on the conduct of the test will be given to the patient. A multi-derivation ECG recording will be detected throughout the duration of the test and followed by a physician experienced in the ECG effort. O2 saturation by oximetry of hens will be recorded continuously. Blood pressure will be recorded at each level. The collection of expired gases in the face mask whose tightness will be verified to measure the fractions inspired and expired in O2 and CO2 (Sensor Medics Vmax229, Yorba Linda, CA, USA) and calculations VO2 max and VCO2. Maximal power (W max) will be recorded. Patients will be encouraged during the test.

06

What researchers measure

Primary outcomes

  1. Oxygen consumption capacity

    Maximum oxygen consumption capacity on cycloergometer during an incremental effort until exhaustion (VO2 max)

    Time frame: At inclusion

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2029, 49 months after the start.

Of 46 non-industry interventional studies with no phase under Axial Spondyloarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 49 months is above that.

Counting every sponsor, half of 46 studies reached it within 28 months; a quarter within 11 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2019
First posted
May 7, 2019
StartActual
Nov 13, 2025
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03940911
Responsible party
Sponsor
First posted
May 7, 2019
Start date
Nov 13, 2025
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Mar 12, 2026

Study contacts

Alain MEYER, MD
Contact
alain.meyer1@chru-strasbourg.fr
+33 3 88 11 67 68

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion